indicated to contain allowable subject matter. *Office Action* at p. 4. No claims have been amended in this Reply.

II. Information Disclosure Statement

The Examiner notes that co-pending U.S. Application No. 10/086,248 (Attorney Docket No. 5725.1032-00) was not considered as Applicants have not provided a copy. *Office Action* at p. 2. Accordingly, Applicants provide a copy with this Reply, and respectfully request consideration of the copending application.

Applicants also submit an Information Disclosure Statement listing WO 99/49837, which was cited by the Examiner in co-pending U.S. Application No. 10/086,248.

III. Double Patenting

Claims 1 and 27 are rejected under the judicially created doctrine of double patenting over claim 1 of U.S. Patent No. 6,585,962. *Office Action* at p. 3. The Examiner believes that claims 1 and 27 are not "patentably distinct" from claim 1 of the '962 patent because it "is directed towards a process of preserving a composition comprising administering a preserving agent chosen from polyamino acids derivatives ... [and the] instant invention is directed towards an anti-wrinkle composition comprising the same polyamino acid." *Id*.

Applicants respectfully disagree. A claim to a process of preserving a composition would not necessarily render obvious claims to an anti-wrinkle composition.

Claim 1 of the '962 patent does not teach or suggest that the preserving agents of formula (I) would be useful or desirable as an anti-wrinkle composition. One of ordinary skill in the art would understand that the preserving agent of the '962 patent affects the

Application No. 10/086,451 Attorney Docket No. 05725.1033

composition itself and <u>not</u> the skin, much less act as an anti-wrinkle composition, as presently claimed.

Claim 1 of the '962 'therefore does not teach or suggest all the elements recited in claims 1 and 27 of the present application, and therefore fails to render these claims obvious. Accordingly, Applicants respectfully request withdrawal of this rejection.

IV. <u>Conclusion</u>

If the Examiner believes a telephone conference would be useful in resolving any outstanding issues, the Examiner is invited to call the undersigned at (202) 408-4162.

Please grant any extensions of time required to enter this response and charge any additional required fees to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW GARRETT & DUNNER, L.L.P

By: / Mark D. Sweet

Reg. No. 41,469

.

DATE: April 13, 2004